Perspective Therapeutics
Update in progressCATX (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on precision targeted alpha therapies (TAT) for cancer. It develops VMT-a-NET for unresectable or metastatic SSTR2-expressing neuroendocrine tumors (Phase 1/2a), VMT01 for MC1R-positive metastatic melanoma (Phase 1/2a), and PSV359 targeting fibroblast activation protein alpha. It also develops Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer and collaborates with Bristol Myers Squibb on [212Pb] VMT01 with nivolumab. Formerly Isoray, renamed 2022. Founded 2004, Seattle.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.11
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE American (ASE)
- LocationUnited States
- CEOMr. Johan M. Spoor
- Founded2004
- Employees163
- Websitewww.perspectivetherapeutics.com
Identifiers
- ISINUS46489V3024
- FIGIBBG000BG5HT7
- CUSIP46489V302
- CIK0000728387